Pharma, biotech may lead follow-on biologics market

04/23/2008 | RPM Report (free registration), The

Some analysts say generic drugmakers will be ill-suited to produce complex follow-on biologics given the case-by-case standard Congress is considering in legislation to create an abbreviated approval pathway. That could leave the door open for pharma and biotech companies to lead the market, this RPM Report analysis says.

View Full Article in:

RPM Report (free registration), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ